Compare Amgen, Inc. (AMGN) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Packaging Corporation of America — how do they compare? Amgen, Inc. trades at $363.02 (market cap $196.12B), while Packaging Corporation of America trades at $228.5 (market cap $20.38B). The key difference: Amgen, Inc. is far larger — about 9.6× Packaging Corporation of America's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | PKG | |
|---|---|---|
Market Cap | $196.12B | $20.38B |
Sector | Health | Technology |
52-Week High | $388.16 | $246.31 |
52-Week Low | $271.18 | $191.41 |
Enterprise Value | $241.41B | $24.21B |
Dividend Yield | 2.77% | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Packaging Corporation of America (PKG) trades at $228.77, up 1.91% with a bullish technical signal. The company reported mixed Q1 2026 earnings with $2.40 EPS beating estimates, though revenue growth faces margin pressure. Analyst consensus is mixed with 34.6% buy ratings and a $253 price target. Recent 20% dividend increase signals management confidence amid elevated input costs.
PKG offers steady dividend income with potential upside to analyst targets, but faces headwinds from cost inflation and competitive pressures. The stock's 27.8 P/E suggests full valuation, requiring sustained earnings growth to justify current levels. Near-term performance hinges on Q2 results and operational efficiency improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
